| Name | Semorinemab |
|---|
| Description | Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein. Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Semorinemab 与人 Tau 蛋白和重组食蟹猴 Tau 蛋白结合的 Kd 值分别为 3.8 和 11.2 nM[1]。 Semorinemab 阻止神经元摄取低聚 Tau[1]。 |
| In Vivo | Semorinemab (3,10 和 30 mg/kg;腹腔注射,每周一次,持续 13 周) 减少 Tau 病状的转基因 (Tg) 小鼠模型中 Tau 的积累[1]。 Animal Model: Tg mouse with the expression of human disease-causing tau mutant (TauP301L-Tg) [1] Dosage: 3, 10 and 30 mg/kg Administration: Intraperitoneal injection; 3, 10 and 30 mg/kg, once weekly for 13 weeks Result: Reduced the accumulation of pathological tau, and dose-dependently decreased pTau212/214 and pTau202/205. |
| References |
| No Any Chemical & Physical Properties |